Dicerna Pharmaceuticals (DRNA) Scheduled to Post Quarterly Earnings on Thursday

Dicerna Pharmaceuticals (NASDAQ:DRNA) will be issuing its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.16). Dicerna Pharmaceuticals had a negative return on equity of 52.17% and a negative net margin of 1,284.93%. The firm had revenue of $3.11 million for the quarter, compared to analyst estimates of $10.59 million. On average, analysts expect Dicerna Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:DRNA opened at $13.01 on Friday. The stock’s fifty day moving average price is $14.93. Dicerna Pharmaceuticals has a 52-week low of $9.31 and a 52-week high of $17.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The firm has a market cap of $888.84 million, a P/E ratio of -10.84 and a beta of 2.17.

DRNA has been the topic of several research reports. B. Riley set a $24.00 price objective on Dicerna Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 3rd. SunTrust Banks reduced their price objective on Dicerna Pharmaceuticals to $20.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. Citigroup upped their price objective on Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Zacks Investment Research raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Dicerna Pharmaceuticals in a report on Monday, July 15th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $21.38.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $12.50, for a total transaction of $20,000,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 21.28% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: What does a dividend yield signify to investors?

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.